

$\mathbf{H}_{1}\mathbf{K}\mathbf{H}\Delta\mathbf{I}=\mathbf{I}$	Participant name	ž						
GRemubamab ErAdication Tria								
	CHI/Date of Birth	ո։						
GREAT-2 GRemubamab E Sponsor Chief Investigator IRAS number		undee-NHS Tayside es Chalmers						
Principal Investigator								
Contact number								
Contact email								
Visit 5 – Treatment phase, treatment dose 2 to be filed in medical notes as source data								
Date of visit:		Participant trial ID						
Please tick to indicate the fo	ollowing has been comple	eted:						
Confirmed participant's identity								
Concomitant medications have been reviewed								
Adverse events have been reviewed								
Exacerbations have been reviewed								
NHS samples:				L				
Full blood count	Full blood count							
Urea & electrolytes,	Urea & electrolytes, creatinine							
Liver function tests	Liver function tests							
Urine pregnancy tes	st performed, if applicable	e		-				
Research samples:				L				
Blood samples pre-	infusion							
Blood samples post	Blood samples post-infusion							
Sputum sample	Sputum sample							
Questionnaires:				L				
Quality of Life-Bron	chiectasis Questionnaire			Г				
				1	1			

Vital signs pre-infusion, during infusion and post-infusion must be recorded and filed in the medical notes e.g. observation chart.

Bronchiectasis Impact Measure Questionnaire



I GRI	FAT-2	Participant name			
GRemubam	ab ErAdication Trial	Hospital ID:			
		CHI/Date of Birth	1:		
Name, dose	firm: was given pre-dose ar		trial medication umented and filed in the medical		
Time of sta infusion cha		documented and file	ed in the medical notes e.g.		
Spirometry What method of bronchodilation was used? nebulised salbutamol Dose mg inhaled salbutamol Dose mcg Number of puffs File copy of spirometry results in notes.					
The following must be filed in the participant's medical notes:					
 Pregnancy test results, if applicable, signed & dated by doctor on delegation log Blood results signed and dated by doctor on delegation log Vital signs taken pre, during and post-trial medication administration Changes to concomitant medications since last visit Any adverse events since last visit Any pulmonary exacerbations since last visit Spirometry results signed and dated by doctor on delegation log Any other notable findings and actions taken Any paper copies of questionnaires If the participant was withdrawn from the trial at this visit document reason 					
The visit has	been carried out as p	er protocol.			
Signature:					
Name:					
Job title:					
Date:					